NT 814

Drug Profile

NT 814

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer KaNDy Therapeutics; NeRRe Therapeutics
  • Class Vascular disorder therapies
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sex hormone disorders; Vasomotor symptoms
  • Discontinued Opioid abuse

Most Recent Events

  • 03 Oct 2017 Discontinued - Phase-II for Opioid abuse in United Kingdom (PO)
  • 27 Sep 2017 Phase-II clinical trials in Vasomotor symptoms in United Kingdom (PO) before September 2017
  • 27 Sep 2017 KaNDy Therapeutics completes a phase IIa trial in Vasomotor symptoms (Post-menopausal) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top